Stock Traders Buy High Volume of Precigen Call Options (NASDAQ:PGEN)

Precigen, Inc. (NASDAQ:PGEN) saw unusually large options trading activity on Thursday. Traders bought 11,343 call options on the stock. This is an increase of approximately 3,908% compared to the average volume of 283 call options.

Precigen Stock Down 3.6 %

Shares of NASDAQ PGEN opened at $1.08 on Friday. Precigen has a twelve month low of $0.65 and a twelve month high of $1.93. The business has a fifty day simple moving average of $0.84 and a two-hundred day simple moving average of $1.09. The firm has a market cap of $316.30 million, a PE ratio of -1.96 and a beta of 1.71.

Institutional Trading of Precigen

Several institutional investors and hedge funds have recently made changes to their positions in the company. Traphagen Investment Advisors LLC bought a new position in Precigen during the 3rd quarter worth about $29,000. Stifel Financial Corp boosted its stake in shares of Precigen by 94.9% during the third quarter. Stifel Financial Corp now owns 32,200 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 15,680 shares in the last quarter. SG Americas Securities LLC increased its holdings in Precigen by 44.2% during the third quarter. SG Americas Securities LLC now owns 45,063 shares of the biotechnology company’s stock valued at $43,000 after buying an additional 13,823 shares during the period. AQR Capital Management LLC increased its holdings in Precigen by 56.7% during the second quarter. AQR Capital Management LLC now owns 50,002 shares of the biotechnology company’s stock valued at $79,000 after buying an additional 18,097 shares during the period. Finally, China Universal Asset Management Co. Ltd. raised its stake in Precigen by 86.6% in the third quarter. China Universal Asset Management Co. Ltd. now owns 55,337 shares of the biotechnology company’s stock worth $52,000 after buying an additional 25,681 shares in the last quarter. 33.51% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “buy” rating and issued a $4.00 price objective on shares of Precigen in a research report on Friday, November 15th. Two investment analysts have rated the stock with a sell rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, Precigen presently has an average rating of “Hold” and an average price target of $7.00.

About Precigen

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.